Cellnovo: Appointment of Javaid Masoud as Chief Technology Officer

PARIS--()--Regulatory News:

Cellnovo Group (Paris:CLNV) (“Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today announces that Javaid Masoud has been appointed as Chief Technology Officer effective immediately.

Mr. Masoud has a proven track record of bringing new medical technologies from concept to product release with a system perspective. Working in the US and Europe, he is recognized for his consistent results and effective leadership in technology and product development by leading multi-functional international teams.

Mr. Masoud was previously Senior Director of Patient Management System R&D at Sorin Group, a leading global medical technology company, where he led the international hardware and software product development teams.

Previously, Mr. Masoud worked at Medtronic USA, Minnesota, where he served as a Technical Fellow, a highly honored position responsible for setting the new technical direction for the Company as a technical educator, mentor and consultant. At Medtronic he directed teams for wireless technologies, embedded firmware development for implantable cardiac defibrillators and external instruments from a systems perspective.

Mr. Masoud holds an M.S in Computer Science from Western Kentucky University USA, and a B.S. in Computer Science from University of Kentucky USA.

Sophie Baratte, CEO of Cellnovo, commented:It is a great pleasure to welcome Javaid to Cellnovo. His wealth of expertise of the international medical technology industry will be invaluable as we continue the commercialization and development of our unique diabetes management system.”

Javaid Masoud, CTO of Cellnovo, said:The Cellnovo approach takes the mobile connectivity we take for granted in other areas of life and applies it to diabetes management to improve the lives of patients. I am very excited to be joining Cellnovo and to have the opportunity to build upon the progress the Company has already made with its proprietary technology.”

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.

For further information please visit www.cellnovo.com

Cellnovo is listed on Euronext, Compartment C
ISIN: FR0012633360 – Ticker: CLNV

Contacts

Cellnovo
Sophie Baratte
Chief Executive Officer
investors@cellnovo.com
or
NewCap
Investor Relations
Emmanuel Huynh, + 33 1 44 71 00 16
or
Media Relations in France
Nicolas Merigeau, + 33 1 44 71 94 98
cellnovo@newcap.eu
or
Consilium Strategic Communications
Media Relations in United Kingdom
Amber Fennell, Chris Gardner, Laura Thornton, +44 20 3709 5700
cellnovo@consilium.com

Contacts

Cellnovo
Sophie Baratte
Chief Executive Officer
investors@cellnovo.com
or
NewCap
Investor Relations
Emmanuel Huynh, + 33 1 44 71 00 16
or
Media Relations in France
Nicolas Merigeau, + 33 1 44 71 94 98
cellnovo@newcap.eu
or
Consilium Strategic Communications
Media Relations in United Kingdom
Amber Fennell, Chris Gardner, Laura Thornton, +44 20 3709 5700
cellnovo@consilium.com